Gene Therapy Researchers React to Field's Pitfalls and Promises

By Woo, Savio L. C. | FDA Consumer, September 2000 | Go to article overview

Gene Therapy Researchers React to Field's Pitfalls and Promises


Woo, Savio L. C., FDA Consumer


THE LAST WORD

The possibility of correcting human genetic disorders by gene therapy caught the imagination of the scientific community as well as that of the public long before the first clinical gene transfer experiment was launched ten years ago. During the ensuing decade, however, the extraordinarily high level of expectation has proven to be grossly optimistic. This prompted Dr. Harold Varmus, then Director of the National Institutes of Health, to appoint two separate committees in the mid-1990s to evaluate the field of gene therapy. The committees independently concluded that clinical applications of gene transfer could not possibly succeed without adequate scientific and technological support, as well as sufficient preclinical studies in relevant animal models of human disease to validate treatment efficacy.

The scientific community has taken these constructive criticisms to heart during the past few years, and dramatic progress has been made in the basic science of viral and non-viral vector development used to transfer genes into patients. As a result, some approaches appear to be working. The Hemophilia B trial currently being conducted at the Children's Hospital of Philadelphia and Stanford University employs intramuscular `delivery of the gene expressing human Factor IX, a protein involved in blood clotting. Patients in this trial have exhibited much improved whole blood clotting times for months after the gene treatment. Children in Paris with X-linked SCID, an inherited disorder that destroys the immune system, are able to live at home normally after genetic treatment of bone marrow stem cells. While both trials are in early phases, the encouraging results do provide proof of the scientific principle that human genetic disorders can be corrected by gene transfer.

In September 1999, clinical experiments in gene transfer research suffered their first patient loss as a direct consequence of the gene treatment itself. The patient was a 19-year-old male with a metabolic disorder who received a high dose of a genetic treatment directly into his liver at the University of Pennsylvania. He died from multi-organ failure induced by an adult respiratory distress syndrome secondary to a systemic inflammatory response to the method used to deliver the new gene.

Initial public response to the tragic incident was rather mild, as it is understood that medical research is not without risks. But public perception of clinical gene therapy took a precipitous turn for the worse after the FDA cited the University of Pennsylvania investigators in December 1999 for multiple protocol violations in the trial. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Gene Therapy Researchers React to Field's Pitfalls and Promises
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.